• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Cardiovascular and renal outcomes in patients with atrial fibrillation and stage 4 –5 chronic kidney disease receiving direct oral anticoagulants: a multicenter retrospective cohort study
AbstractThe role of direct oral anticoagulants (DOAC) in patients with atrial fibrillation (AF) and stage 4 –5 chronic kidney disease (CKD) is controversial. Electronic medical records from 2012 to 2021 were retrieved for patients with AF and stage 4–5 CKD receiving oral anticoagulants. Patients were separated into those receiving DOACs (dabigatran, rivaroxaban, apixaban, or edoxaban) or vitamin K ant agonists (VKA). Primary outcomes included ischemic stroke (IS), systemic thrombosis (SE), major bleeding, gastrointestinal bleeding, hemorrhagic stroke, acute myocardial infarction, cardiovascular death, and all-cause dea...
Source: Journal of Thrombosis and Thrombolysis - August 21, 2023 Category: Hematology Source Type: research

Clinical Outcomes of Prolonged Antiplatelet Therapy after Percutaneous Coronary Intervention in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis
Conclusions: Prolonged DAPT might decrease the risk of mortality, MACE, and stroke in patients with CKD without any significant difference in bleeding or revascularization. Additional studies are required to determine whether long-term DAPT could be considered for most CKD patients after PCI.Blood Purif
Source: Blood Purification - December 6, 2022 Category: Hematology Source Type: research

Cardiovascular mortality due to pulmonary embolism in subjects with renal impairment: patients’ comorbidities are crucial
Abstract we read with great interest the paper by Ocak et al. (1). The authors found that the age‐ and sex‐standardized mortality rate (SMR) for pulmonary embolism (PE) was 12.2 (95% CI 10.2‐14.6) times higher in dialysis patients than in the general population. Such SMR was even higher than that of myocardial infarction (MI) (11.0, 95% CI 10.6‐11.4), stroke (8.4 (95% CI 8.0‐8.8), and other cardiovascular disease (8.3, 95% CI 8.0‐8.5) On the one hand, the association between the different grade of impaired renal function and MI received important confirmation (2), and also a recent study from our group conducte...
Source: Journal of Thrombosis and Haemostasis - April 4, 2013 Category: Hematology Authors: Fabio Fabbian, Francesco Dentali, Walter Ageno, Roberto Manfredini Tags: Letter Rebuttal Source Type: research

Cerebral Blood Flow in Patients With Peritoneal Dialysis by an Easy Z‐Score Imaging System for Brain Perfusion Single‐Photon Emission Tomography
In conclusion, all PD patients in the present study had decreased rCBF irrespective of MMSE scores.
Source: Therapeutic Apheresis and Dialysis - June 26, 2014 Category: Hematology Authors: Rei Isshiki, Shuzo Kobayashi, Masao Iwagami, Daimu Tsutumi, Yasuhiro Mochida, Kunihiro Ishioka, Machiko Oka, Kyoko Maesato, Hidekazu Moriya, Takayasu Ohtake, Sumi Hidaka Tags: Original Article Source Type: research

Piperacillin/tazobactam‐induced neurotoxicity in a hemodialysis patient: A case report
This report presents a case of a hypertensive and diabetic 67‐year‐old woman in regular hemodialysis, which previously had a stroke. She was hospitalized presenting pneumonia, which was initially treated with cefepime. Two days after treatment, she presented dysarthria, left hemiparesis, ataxia, and IX and X cranial nerves paresis. Computed tomography showed no acute lesions and cefepime neurotoxicity was hypothesized, and the antibiotic was replaced by piperacillin/tazobactam. The neurologic signs disappeared; however, 4 days after with piperacillin/tazobactam treatment, the neurological manifestations returned. A new...
Source: Hemodialysis International - July 1, 2014 Category: Hematology Authors: Precil Diego M. M. Neves, Fernanda M. Freitas, Christiane A. Kojima, Beatriz L. Carmello, Rodrigo Bazan, Pasqual Barretti, Luis C. Martin Tags: Case Report Source Type: research

Clopidogrel Use in End‐Stage Kidney Disease
In conclusion, current evidence suggests that ESKD patients may not derive the same benefits from clopidogrel therapy as the general population and this therapy may be associated with harm. Properly designed observational studies and randomized controlled trials are needed to establish the role of clopidogrel in patients with ESKD, the use of platelet assays to tailor therapy, and the role of other antiplatelet agents such as prasugrel or ticagrelor in patients who exhibit high on‐treatment residual platelet reactivity.
Source: Seminars In Dialysis - November 1, 2014 Category: Hematology Authors: Bassem Y. Tanios, Houssam S. Itani, Deborah L. Zimmerman Tags: Review Source Type: research

Antithrombotic therapy in end ‐stage renal disease
Abstract The delicate balance of risk vs. benefit of using antiplatelet and antithrombotic agents in the general population is well established. The decision to use these agents in the end stage renal disease (ESRD) population remains complex and difficult. The concomitant association of a prothombotic state with high risk of bleeding in the ESRD population requires individualization and careful clinical judgment before implementing such therapy. There remains a paucity of clinical trials and lack of substantial evidence in literature for safe and effective use of antithrombotic drugs in patients with advanced chronic kidn...
Source: Hemodialysis International - April 1, 2017 Category: Hematology Authors: Svetha Chunduri, Jon E. Folstad, Tushar J. Vachharajani Tags: Review Article Source Type: research